





**DenSeeMammo**  
**automatically**  
**assesses**  
**breast density**  
**simulating visual**  
**evaluation in a reproducible way.**



- DenSeeMammo is a state-of-the-art tool for assessing breast density in a way comparable to **visual assessment** by radiologists specialized in breast imaging.
- DenSeeMammo measures breast density and shows **excellent agreement** with visual assessment by qualified radiologists' consensus.
- DenSeeMammo provides a 2D standardized breast density value for each patient, along with a **BI-RADS (5th Edition) breast density category**.
- DenSeeMammo analyzes processed digital 2D mammograms in a **fully automated** comparison procedure.
- DenSeeMammo has received **510(k) clearance by the FDA** for GE equipment.

## DenSeeMammo Workflow

- Easy-to-use, seamless workflow
- Output on workstation (DICOM SC and PDF files)
- Easily integrated into a patient report




## DenSeeMammo Installation

- Easy to install: 1 computer, network connected
- Smooth integration: DICOM compatibility
- Tailored to each customer's unique workflow
- Fast and reactive remote service
- Secure: HIPAA compliant

## DenSeeMammo & MammoRisk

- MammoRisk uses an innovative proprietary risk prediction model to determine a **woman's risk of developing breast cancer** integrating breast density category
- **DenSeeMammo can be integrated with MammoRisk** in order to get a complete solution
- MammoRisk reports are readily accessible and easy to understand for the **clinician** to discuss with the **patient**
- MammoRisk software provides an individualized breast cancer **screening plan** based on current screening guidelines



**Statlife** is an innovative company specializing in statistics and data mining using 4P Medicine: Predictive, Preventive, Personalized and Participative. DenSeeMammo and MammoRisk were developed in collaboration with Gustave-Roussy, the largest comprehensive cancer center in Europe, and the Breast Cancer Surveillance Consortium in the U.S. MammoRisk is the subject of a patent application using the "Nearest Neighbor" methodology for the prediction of disease (patent number EP2278510).

Statlife, Math for Medicine

© Statlife 2017

[mammorisk.com/us](http://mammorisk.com/us)

 DenSeeMammo